Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

67 results
Display

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?

Chun HS, Lee M

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Liang LY, Lee HW, Wong VWS, Yip TCF, Tse YK, Hui VWK, Lui GCY, Chan HLY, Wong GLH

Background/Aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Another oral antiviral treatment, but still far away from hepatitis B virus cure

Tseng TC

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW

Clinical practice guidelines are important for guiding the management of specific diseases by medical practitioners, trainees, and nurses. In some cases, the guidelines are utilized as a reference for health...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trends in the prevalence of chronic liver disease in theKorean adult population, 1998–2017

Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, Park HY, Kim DJ

Background/Aims: Data on the trends in the prevalence of chronic liver disease (CLD) in Korea are scarce. This study aimed to evaluate whether the CLD prevalence changed between 1998–2001 and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation

Kim HJ, Kim SY, Shin SP, Yang YJ, Bang CS, Baik GH, Kim DJ, Ham YL, Choi EY, Suk KT

Background/Aims: Enzymatic analysis of aspartate/alanine aminotransferase (AST/ALT) does not exactly represent the progression of liver fibrosis or inflammation. Immunoassay for AST (cytoplasmic [c] AST/mitochondrial [m] AST) and ALT (ALT1/ALT2) has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The fibrogenic process and the unleashing of acute-on-chronic liver failure

López-Sánchez GN, Dóminguez-Pérez M, Uribe M, Nuño-Lámbarri N

Acute-on-chronic liver failure (ACLF) is a life-threatening condition characterized by a rapid deterioration of previously well-compensated chronic liver diseases. One of the main obstacles in ACLF is the lack of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand

Laiwatthanapaisan R, Sripongpun P, Chamroonkul N, Dechaphunkul A, Sathitruangsak C, Sakdejayont S, Kongkamol , Piratvisuth T

BACKGROUND/AIMS: Hepatitis B virus reactivation (HBVr) following chemotherapy (CMT) is well-known among hematologic malignancies, and screening recommendations are established. However, HBVr data in solid organ malignancy (SOM) patients are limited....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients

Yoon EL

Improved management of chronic hepatitis B patients with oral nucleos(t)ide analogues has increased the number of these patients who are getting older and have other accompanying comorbidities. These comorbidities frequently...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma

Lee HW

Multiple studies have shown that oral antiviral therapies reduced the incidence of hepatocellular carcinoma (HCC) and improved the survival of patients with chronic hepatitis B when compared with that of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Patchy echogenicity of the liver in patients with chronic hepatitis B does not indicate poorer elasticity

Wu S, Tu R, Liang X

PURPOSE: This study was conducted to investigate whether the presence of patchy echogenicity in the liver of patients with chronic hepatitis B (CHB) is predictive of liver stiffness. METHODS: A total...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Cho YY, Choi YH, Yu SJ, Cho EJ, Lee JH, Kim YJ, Yoon JH

BACKGROUND/AIMS: Tenofovir disoproxil fumarate (TDF) is potentially nephrotoxic in chronic hepatitis B patients. Hepatocellular carcinoma (HCC) patients treated using transarterial chemoembolization (TACE) are at an increased risk of renal injury....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

Kim DS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU

BACKGROUND/AIMS: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?

Yu JH, Lee JW

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The epidemiology of hepatitis B virus infection in Korea

Yim SY, Kim JH

The global burden of hepatitis B virus (HBV) infection is profound, and represents a public health threat as chronic infection can lead to liver cirrhosis, hepatocellular carcinoma, and death. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice

Song JE, Lee CH, Kim BS

BACKGROUND/AIMS: The optimal management of chronic hepatitis B (CHB) patients with partial virologic response (PVR) to tenofovir disoproxil fumarate (TDF) remains unclear. We aimed to evaluate the long-term efficacy of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Updated Treatment of Chronic Hepatitis B

Yoon EL, Yim HJ

Chronic hepatitis B virus (HBV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma in Korea. The prevalence of HBV infection is gradually decreasing in Korea, but 3.0%...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What's Different?

Kim JH

The clinical practice guideline for the management of chronic hepatitis B (CHB) was originally enacted in 2004 by the Korean Association for the Study of the Liver in order to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunotherapy for Chronic Hepatitis B Virus Infection

Bertoletti A, Le Bert N

While new therapies for chronic hepatitis C virus infection have delivered remarkable cure rates, curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal. Although current direct...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B

Kim CW, Kim CS, Kim HY, Lee CD, Yu K, Llamoso C, Lee HJ

BACKGROUND/AIMS: Entecavir (ETV) is effective and safe antiviral agent against hepatitis B virus (HBV) in clinical and real-world setting but, most studies were performed in single institute or have limitation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr